Kronox Lab Sciences Share Price Target 2026, 2027, 2028, 2029, 2030

Kronox Lab Sciences share price today

Kronox Lab Sciences makes high-purity inorganic chemicals — phosphates, sulphates and metallic salts — sold into pharmaceutical, nutraceutical, food and laboratory-reagent uses. The catalogue runs to roughly 185 products, most of them sold in small volumes at high purity specifications. It is a Vadodara-based business of a type India has plenty of on paper and very few of at this level of return.

At the 6 August 2026 cut-off the share closed at ₹166.78, a reconciled market capitalisation near ₹619 crore on trailing EPS of ₹7.45. The quote above updates live; the ratios and scenarios below are fixed to that session.

The numbers are the attraction and the caution at once. Return on capital employed of 36%, a five-year average nearer 46%, and an operating margin approaching 34% describe a genuinely high-quality small chemical business. Five-year sales growth of about 10.1% is the slowest in this batch. And the company has only been listed since June 2024, so almost none of that record has been observed under public disclosure.

Purity is the product

The commercial logic here is narrow and worth stating precisely. Kronox does not invent molecules. It takes well-known inorganic salts and manufactures them to specifications — trace-metal limits, particle size, consistency batch to batch — that a pharmaceutical or food customer can write into a filing. The chemistry is generic; the process control is not.

Layer	What Kronox supplies	Why the customer pays for it
Product family	Phosphates, sulphates, metallic and specialty salts	Standard chemistry, non-standard purity
Grades	Excipient, reagent, nutraceutical and food grades	Each grade carries its own documentation burden
Catalogue breadth	About 185 products	Single-supplier convenience across a long tail
Volume profile	Many small orders rather than few large ones	Reduces single-customer dependence
Qualification	Named in customer specifications and filings	Slow to win, slow to lose

The long tail is the important structural feature. A supplier of 185 low-volume grades has diversified revenue almost by construction, and it faces less pricing pressure than a supplier of one high-volume commodity. It also grows slowly, because each new grade adds a small amount of revenue and every large step requires either a new customer segment or a capacity decision.

What the reported quarters actually show

Disclosure here is thin by the standards of the rest of this batch, and we would rather say so than fill the gap. The most recent quarter we can source cleanly is the March 2026 quarter, which showed revenue of about ₹28.27 crore, up roughly 4.5% year on year, with net profit of about ₹8.00 crore, up roughly 26.6%.

Q4 FY26 measure	Reported outcome	Reading
Revenue	About ₹28.27 Cr	Growth of roughly 4.5% year on year
Net profit	About ₹8.00 Cr	Growth of roughly 26.6% year on year
Implied net margin	Roughly 28%	Consistent with the 33.86% operating margin
Profit versus revenue growth	Profit grew about six times faster	Margin, mix or cost, not volume

The board met on 12 August 2026 to approve the June-quarter results, after our cut-off, so they sit outside the valuation base below. They are worth stating anyway, because they cut against the optimistic reading: June-quarter sales of about ₹28.39 crore were barely ahead of the March quarter, while net profit of roughly ₹7.30 crore was lower than the ₹8.00 crore recorded three months earlier. A quarter of flat revenue and falling profit does not settle the growth question, but it certainly does not resolve it favourably.

Trailing EPS of ₹7.45 on roughly 3.7141 crore shares implies annual profit near ₹27.7 crore, which sits sensibly against a March quarter of ₹8.00 crore and supports the view that the reported ratios are internally consistent.

The growth problem in one comparison

Set the return ratios beside the growth ratios and the tension is immediate.

Measure	Kronox five-year record	What it says
Sales CAGR	10.14%	Slow, and the slowest in this batch
Profit CAGR	23.29%	Roughly half of it came from margin, not volume
Operating margin	33.86%	Already high
Average ROCE	46.38%	Historically exceptional
Current ROCE	36.00%	Still excellent, but below its own average

A company growing sales at 10% and profit at 23% has been converting operating leverage into earnings. That works until margin stops expanding. Current ROCE sitting roughly ten points below the five-year average is the first quiet signal that the conversion is maturing — more capital is now employed per rupee of profit than was historically the case.

None of that makes it a poor business. It makes 22 times earnings a full price for a company whose demonstrated revenue growth is barely into double digits.

A short listing history is a real analytical limit

Kronox listed in June 2024. That means the five-year ROCE and margin averages quoted above are largely drawn from pre-listing financials, prepared before the company was subject to quarterly public reporting, analyst questioning and the scrutiny that follows a listed float.

We are not suggesting anything improper. We are pointing out that the evidence base is weaker than the same numbers would be for a company with a decade of audited quarterly filings. There is no observed behaviour through a downturn, no history of how management guides and then delivers, and no track record of capital allocation decisions made under public scrutiny. For a stock trading at five times book, that absence deserves a discount rather than the benefit of the doubt.

Valuation at the fixed price

At ₹166.78 the shares traded at about 22.4 times trailing earnings and 5.3 times book. The 52-week range ran ₹96.00 to ₹180.50, so the cut-off price sat roughly 7.6% below the high after a substantial run from the low.

Valuation metric	6 August 2026 value	Basis
Share price	₹166.78	Exchange close on the cut-off date
Reconciled market capitalisation	₹619 Cr	Price times about 3.7141 crore shares
Recalculated P/E	22.39×	₹166.78 divided by trailing EPS of ₹7.45
Recalculated price to book	5.33×	₹166.78 divided by ₹31.30 book value per share
Recalculated PEG	About 0.96	P/E divided by the 23.29% five-year profit CAGR
Dividend yield	About 0.30%	Token distribution; earnings are retained
52-week range	₹96.00 – ₹180.50	Cut-off price about 7.6% below the high

Because the available valuation fields were captured on a different day from the price, market capitalisation and every per-share ratio above were recomputed against the same ₹166.78 close and roughly 3.7141 crore shares, so that price, earnings and book value share one denominator.

Twenty-two times earnings is not extreme for a 36% ROCE business. It is demanding for one growing sales at 10% with two years of listed history, and that combination is why the position on this name is to watch rather than to act.

Size and liquidity change the risk

At under ₹1,000 crore of market capitalisation, this is a company where daily traded value is small, institutional coverage is thin, and the price can move sharply on modest order flow. Combined with the short listing record, the practical consequence is that both entry and exit are more expensive and less certain than the headline quality would suggest. Position size should reflect that rather than the return ratios.

Valuation framework: paying for quality, waiting on volume

The scenario model compounds trailing EPS of ₹7.45 from the cut-off. It applies 147/365 of a year’s growth to the 2026 row and one further full year to each later row, then applies an exit price-to-earnings multiple. Values round to the nearest ₹5 and exclude dividends.

Scenario	Annual EPS growth	Exit P/E	Operating interpretation
Bear	9%	14×	Volume growth stays near the five-year rate and the multiple normalises
Base	15%	20×	Catalogue expansion and new customer grades lift growth modestly
Bull	21%	26×	Capacity addition converts into export and regulated-market volume

Even the bull case here assumes 21% earnings growth, not the 23% profit CAGR of the past five years, because that historical figure was partly margin-driven and the margin is already high. Assuming the past repeats would be the single easiest way to overpay for this company.

Kronox Lab Sciences share price target 2026 to 2030

Those three assumption sets resolve into the yearly grid above. As always it is arithmetic on a stated base rather than a forecast, and the spread between bear and bull is wide precisely because the volume trajectory is the open question.

What would change the thesis

The case strengthens if revenue growth moves durably above 15%, if capacity additions are announced with identified customers rather than in the abstract, if regulated-market or export grades become a disclosed share of revenue, and if several quarters of public reporting establish that management guides accurately.

It weakens if sales growth stays near 10% while the multiple holds above 20 times, if ROCE continues drifting below its historical average as capital employed rises, if a small number of customers turn out to drive the long tail, or if margin compresses as the product mix shifts toward higher-volume grades.

Quarterly monitoring scorecard

Question	Constructive evidence	Warning sign
Is revenue growth accelerating?	Consecutive quarters above 15%	Growth stays in single digits
Is capital still productive?	ROCE stabilises near or above 36%	Continued drift below the five-year average
Is the catalogue working?	New grades add disclosed revenue	Growth concentrates in a few products
Is margin holding?	Operating margin near 34%	Sustained compression below 28%
Is disclosure improving?	Segment and customer detail expands	Reporting stays minimal
Is guidance reliable?	Management delivers what it indicated	Repeated shortfalls against commentary

What to weigh at the current price

Kronox is a high-quality manufacturing business by every return measure available, run without leverage and without pledged promoter shares, in a niche where purity and qualification create genuine retention. That much is clear from the numbers.

What is not clear is why it should compound faster from here than the 10% sales growth it has averaged, and 22 times earnings requires it to. Add a listing history under two years and a market capitalisation that makes the shares hard to trade in size, and the sensible response is to keep this on the list and let two or three more quarters of public reporting settle the growth question. The quality is not in doubt; the price already assumes it.

FAQ

What is the Kronox Lab Sciences share price target for 2030?

The grid above gives bear, base and bull values from trailing EPS, an assumed growth rate and an exit multiple. The spread is deliberately wide because the company’s volume growth, not its margin, is the genuine unknown.

What does Kronox Lab Sciences manufacture?

High-purity inorganic chemicals — phosphates, sulphates and metallic salts — across roughly 185 products, supplied as excipient, reagent, nutraceutical and food grades to pharmaceutical and laboratory customers.

Why is Kronox growth slower than its profit growth?

Because much of the earnings growth came from margin expansion rather than selling more. Sales compounded at about 10.1% over five years while profit compounded at about 23.3%, and a 34% operating margin has limited room to widen.

What is the biggest risk in Kronox Lab Sciences shares?

Paying a growth multiple for a business with modest demonstrated growth and a listing record under two years. Small size and thin traded volume make both entry and exit more expensive than the headline quality suggests.

Was Kronox a recent listing?

Yes, it listed in June 2024. Much of the five-year return and margin history quoted by data providers therefore predates public reporting, which is a reason to weigh it less heavily than an equivalent long-listed record.

When does Kronox Lab Sciences report its next result?

Check the results calendar and confirm the board-meeting date from the company’s own exchange filing. The June-quarter results were approved on 12 August 2026, after the cut-off used here, and showed flat revenue with profit below the preceding quarter.

Related research

• Vinati Organics share price target
• Epigral share price target
• Fineotex Chemical share price target

Sources and methodology

• Kronox Lab Sciences on Screener
• Kronox Lab Sciences quarterly financials
• Kronox Lab Sciences results history
• Kronox Lab Sciences analyst coverage

Return and margin metrics are Screener figures captured on 6 August 2026, with the market price and 52-week range taken from exchange closing data for the same session; per-share ratios were recomputed against that one price. March-quarter figures are as reported and are quoted approximately where the source itself rounded. June-quarter results were approved after our cut-off and are deliberately excluded. The live quote does not regenerate the fixed grid.

---

This article is research and education, not personalised investment advice or a recommendation to transact. Gale is not a SEBI-registered investment adviser. Price targets are scenario arithmetic, not promises. Verify current filings, liquidity, corporate actions and suitability, and consult a registered adviser before acting.